Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.

Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk. 2019 07; 19(7):431-440.e13.

View in: PubMed

subject areas

Administration, Oral
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Diamines
Female
Genes, ras
Humans
Leukemia, Myeloid, Acute
Male
MAP Kinase Kinase 1
MAP Kinase Kinase 2
Middle Aged
Mutation
Proto-Oncogene Proteins c-akt
Pyrazoles
Pyridones
Pyrimidinones
Treatment Outcome
Young Adult

authors with profiles

Loren Joseph
Wendy Stock
Olatoyosi Odenike